Meeting
2023 ASCO Genitourinary Cancers Symposium
Real world (rw) homologous recombination repair (HRR) gene mutation testing trends in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the United States (US).
Authors
Pedro C. Barata
Tulane University, New Orleans, LA
Pedro C. Barata , Rachel Montgomery , Matthew Last , Liane Gillespie-Akar , Jonathan Nazari , Bhakti Arondekar , Alexander Niyazov
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 98)
DOI
10.1200/JCO.2023.41.6_suppl.98
Abstract #
98
Poster Bd #
D1
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Quality Care Symposium
Understanding testing for and treatment of homologous recombination repair (HRR)-mutated metastatic castrate-resistant prostate cancer (mCRPC): A quality initiative by Integra Connect PrecisionQ.
First Author: Roby Antony Thomas
Poster
2022 ASCO Genitourinary Cancers Symposium
ADAM: A multicenter, non-interventional, prospective cohort study for determination of prevalence of homologous recombination repair genes mutations (HRRm) in metastatic castrate resistant prostate cancer (mCRPC)—Interim analysis.
First Author: Boris Alexeev
Poster
2020 Genitourinary Cancers Symposium
Development of a predictive model of PSA response to a switch from prednisone to dexamethasone in metastatic castrate-resistant prostate cancer patients biochemically progressing on abiraterone.
First Author: Reeta Barua
Poster
2019 ASCO Annual Meeting
High dose testosterone in men with metastatic castrate-resistant prostate cancer (mCRPC) and homologous recombination deficiency (HRD).
First Author: Julia Chen